BPMC Blueprint Medicines Corporation Net earnings per share growth forecast for next year

Corporate company logo of Blueprint Medicines (BPMC)

Blueprint Medicines is building a closed-loop precision oncology ecosystem by linking clinics with its own treatment protocols. The target net income per share growth rate reflects the current consensus, where the value 196.50 determines the parameter status. Despite pressure from government programs and competition, the rapid success of Ayvakit is generating a powerful cash flow, bringing the company closer to stable profitability.

BPMC: Blueprint Medicines Corp. Net earnings per one share growth forecast for next year 07/04/2022 - 08/02/2025

Financial and market metric breakdowns for Blueprint Medicines Corp. (BPMC)

- share price and consensus valuation forecast:
Fundamental company analysis:Blueprint Medicines Corp, BPMC
Brand item of Blueprint Medicines Corporation

For investors in Blueprint Medicines (BPMC), this indicator serves as a key tool for assessing future profitability through the lens of expected earnings per share. The modeled EPS growth for the next fiscal year is calculated as the percentage change in projected net income, which in the case of Blueprint Medicines (BPMC) confirms high margins driven by the premium positioning of Ayvakit and a lack of competitors in mastocytosis therapy.

Competing companies

GMAB (Genmab Corp) - Earnings growth forecast for next year|Earnings growth forecast for next year exelixis.com|Net earnings per share growth forecast for next year Nuvalent (NUVL)|KYMR (Kymera) - Expected earnings per share trend next year|Earnings growth forecast for next year IDYA (IDEAYA Biosciences Inc)|Net earnings per one share growth forecast for next year Enliven Pharma|ORIC Pharmaceuticals Inc - Earnings growth forecast for next year|Expected net earnings per share growth next year Relay Therapeutics, Inc.|NRIX (Nurix Therapeutics) - Expected earnings per share growth for next year|TYRA: Projected earnings per share increase next year|VSTM (verastem.com) - Earnings growth forecast for next year|Expected net earnings per share growth next year Monte Rosa Tx GLUE|Earnings growth forecast for next year CGEM|Immuneering - Projected earnings per share growth rate for next year|C4 Therapeutics - Expected earnings per share growth for next year|Expected earnings per share trend next year BDTX|RPTX: Expected earnings per share growth for next year|PMV Pharma - Projected earnings per share increase next year|KPTI: Earnings growth forecast for next year|Propanc Biopharma Inc. - Expected earnings per share trend next year|BGMS (Cyclacel) - Earnings growth forecast for next year|Expected net earnings per share growth next year aadibio.com AADI|Net earnings per share growth forecast for next year Aileron Therapeutics Inc (ALRN)|GLYC (GlycoMimetics) - Expected earnings per share trend next year|Earnings growth forecast for next year SWTX (SpringWorks Therapeutics, Inc)